Search jobs Precigen Provides Latest Clinical Developments at Virtual R&D Update Event
GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today held an R&D virtual event to provide an update on the latest progress for its clinical pipeline.
The event showcased data from several of Precigen s most advanced clinical programs PRGN-3005 UltraCAR-T®, PRGN-3006 UltraCAR-T® and AG019 ActoBiotics
TM with presentations and discussions from Precigen executives and key opinion leaders, including Dr. Helen Sabzevari, President and CEO of Precigen, Dr. Pieter Rottiers, CEO of Precigen ActoBio, Dr. Mary L. (Nora) Disis, faculty member at the University of Washington and Fred Hutchinson Cancer Research Center and one of the lead investigators for the PRGN-3005 clinical study, and Dr. Kevan Herold, Professo